Treatment | Day of study | |||||
---|---|---|---|---|---|---|
3 | 10 | 17 | 24 | 31 | 38 | |
Control | ||||||
Range | 17–27 | 17–27 | 23–28 | 21–27 | 17–29 | 19–28 |
Arithmetic mean (AM) | 21.88 | 20.88 | 25.00 | 24.25 | 23.13 | 23.13 |
Geometric mean (GM)a | 21.64 | 20.69 | 24.95 | 24.18 | 22.86 | 22.94 |
Simparica Trio™ | ||||||
Range | 0–0 | 0–0 | 0–2 | 0–0 | 0–1 | 0–0 |
Arithmetic mean (AM) | 0.00 | 0.00 | 0.38 | 0.00 | 0.13 | 0.00 |
AM Efficacy (%) | 100 | 100 | 98.50 | 100 | 99.46 | 100 |
Geometric mean (GM)a | 0.00 | 0.00 | 0.25 | 0.00 | 0.09 | 0.00 |
GM Efficacy (%) | 100 | 100 | 98.99 | 100 | 99.60 | 100 |
Test statistic vs control | t(34)= 28.97 | t(34)= 28.53 | t(48)= 27.10 | t(41)= 23.66 | t(33)= 17.13 | t(36)= 29.05 |
P-value vs control | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
NexGard Spectra® | ||||||
Range | 0–0 | 0–0 | 0–0 | 0–1 | 0–2 | 0–1 |
Arithmetic mean (AM) | 0.00 | 0.00 | 0.00 | 0.25 | 0.50 | 0.25 |
AM Efficacy (%) | 100 | 100 | 100 | 98.97 | 97.84 | 98.92 |
Geometric mean (GM)a | 0.00 | 0.00 | 0.00 | 0.19 | 0.36 | 0.19 |
GM Efficacy (%) | 100 | 100 | 100 | 99.22 | 98.41 | 99.18 |
Test statistic vs control | t(34)= 28.97 | t(34)= 28.53 | t(48)= 29.10 | t(41)= 22.39 | t(33)= 15.89 | t(36)= 27.47 |
P-value vs control | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
Test statistic vs Simparica Trio™ | t(34)= 0.00 | t(34)= 0.00 | t(48)= -2.00 | t(41)= 1.27 | t(33)= 1.24 | t(36)= 1.59 |
P-value vs Simparica Trio™ | 1.0000 | 1.0000 | 0.0511 | 0.2109 | 0.2225 | 0.1217 |